We are live on !
Find out more
EAM
Exome Asset Management Portfolio holdings
AUM
$162M
Turnover
47.89%
1-Year Est. Return
259.04%
This Fund
S&P 500
This Quarter Est. Return
+28.52%
1 Year Est. Return
+259.04%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$162M
AUM Growth
-$31.2M
(-16%)
Cap. Flow
-$33.6M
Cap. Flow % of AUM
Cap. Flow %
-20.7%
Top 10 Holdings %
Top 10 Hldgs %
44.55%
Holding
71
New
15
Increased
1
Reduced
32
Closed
19
Avg Time Held
Equity + Options
0.7
years
Top 10 Avg Time Held
Equity + Options
0.7
years
Top 20 Avg Time Held
Equity + Options
0.6
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TG Therapeutics
TGTX
|
+$6.75M |
| 2 |
Abivax
ABVX
|
+$5.31M |
| 3 |
AstraZeneca
AZN
|
+$2.27M |
| 4 |
uniQure
QURE
|
+$2.12M |
| 5 |
Ocular Therapeutix
OCUL
|
+$1.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$5.78M |
| 2 |
Enliven Therapeutics
ELVN
|
+$5.09M |
| 3 |
Elevance Health
ELV
|
+$4.3M |
| 4 |
BridgeBio Pharma
BBIO
|
+$3.44M |
| 5 |
Apellis Pharmaceuticals
APLS
|
+$3.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Guardant Health
GH
$21.2B
| $10.1M | 6.25% |
67,500
-15,236
| -18% | -$1.66M |
2024 Q1
9 quarters
|
|
|
2
Praxis Precision Medicines
PRAX
$7.26B
| $9.11M | 5.62% |
27,205
-18,264
| -40% | -$5.78M |
2025 Q2
4 quarters
|
|
|
3
TG Therapeutics
TGTX
$8.16B
| $9.06M | 5.59% |
+164,915
| New | +$6.75M |
2026 Q2
0 quarters
|
|
4
Cogent Biosciences
COGT
$5.21B
| $8.15M | 5.03% |
210,523
-68,010
| -24% | -$2.38M |
2025 Q1
5 quarters
|
|
5
Ionis Pharmaceuticals
IONS
$7.38B
| $6.99M | 4.31% |
88,177
-21,887
| -20% | -$1.65M |
2024 Q4
6 quarters
|
|
6
Eli Lilly
LLY
$1.11T
| $6.59M | 4.06% |
5,492
-1,520
| -22% | -$1.55M |
2023 Q4
10 quarters
|
|
|
7
Abivax
ABVX
$7.64B
| $6.25M | 3.85% |
+46,878
| New | +$5.31M |
2026 Q2
0 quarters
|
|
8
Alumis Inc
ALMS
$821M
| $5.75M | 3.55% |
204,418
-74,758
| -27% | -$1.74M |
2025 Q3
3 quarters
|
|
9
Cytokinetics
CYTK
$8.71B
| $5.12M | 3.16% |
60,056
-43,662
| -42% | -$3.14M |
2024 Q3
7 quarters
|
|
|
10
Enliven Therapeutics
ELVN
$2.84B
| $5.09M | 3.14% |
100,203
-119,888
| -54% | -$5.09M |
2025 Q4
2 quarters
|
|
11
Vera Therapeutics
VERA
$2.08B
| $4.17M | 2.58% |
97,276
-17,715
| -15% | -$660K |
2025 Q2
4 quarters
|
|
12
UnitedHealth
UNH
$365B
| $4M | 2.46% |
9,612
-3,250
| -25% | -$1.2M |
2025 Q4
2 quarters
|
|
13
10x Genomics
TXG
$9.11B
| $3.93M | 2.43% |
102,629
-51,565
| -33% | -$1.35M |
2025 Q2
4 quarters
|
|
14
Natera
NTRA
$57.6B
| $3.75M | 2.31% |
13,800
-4,850
| -26% | -$1.03M |
2023 Q4
10 quarters
|
|
|
15
uniQure
QURE
$1.54B
| $3.73M | 2.3% |
+81,056
| New | +$2.12M |
2026 Q2
0 quarters
|
|
16
Rhythm Pharmaceuticals
RYTM
$6.07B
| $3.58M | 2.21% |
32,209
-8,372
| -21% | -$757K |
2026 Q1
1 quarter
|
|
17
Maze Therapeutics
MAZE
$1.65B
| $3.42M | 2.11% |
114,692
+26,182
| +30% | +$686K |
2026 Q1
1 quarter
|
|
18
Monte Rosa Therapeutics
GLUE
$909M
| $3.32M | 2.05% |
137,115
-42,369
| -24% | -$801K |
2026 Q1
1 quarter
|
|
19
MoonLake Immunotherapeutics
MLTX
$830M
| $3.24M | 2% |
166,493
-48,883
| -23% | -$886K |
2026 Q1
1 quarter
|
|
20
Alkermes
ALKS
$7.21B
| $3.21M | 1.98% |
61,336
-22,767
| -27% | -$889K |
2026 Q1
1 quarter
|
|
21
Liquidia Corp
LQDA
$3.05B
| $3.13M | 1.93% |
39,224
-6,572
| -14% | -$352K |
2025 Q2
4 quarters
|
|
22
United Therapeutics
UTHR
$23.3B
| $2.93M | 1.81% |
5,410
-1,643
| -23% | -$925K |
2025 Q3
3 quarters
|
|
23
Glaukos
GKOS
$9.8B
| $2.78M | 1.71% |
19,862
-1,012
| -5% | -$128K |
2025 Q3
3 quarters
|
|
24
Arrowhead Research
ARWR
$8.08B
| $2.63M | 1.62% |
32,214
-13,507
| -30% | -$998K |
2025 Q3
3 quarters
|
|
25
Agios Pharmaceuticals
AGIO
$2.08B
| $2.62M | 1.61% |
70,500
-54,560
| -44% | -$1.66M |
2025 Q4
2 quarters
|
|
Similar funds
STCOSD
CCA
MIM
CFG
CCM
RWA
VB
TA
Exome Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, Exome Asset Management held 71 positions worth $162M, down 16% from $193M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Exome Asset Management withdrew a net $33.6M in Q2 2026, closing 19 positions and reducing 32 holdings. Its most notable exit was Elevance Health, an estimated $4.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 88% a quarter earlier.
Against the trend, Exome Asset Management opened a new position in TG Therapeutics worth $9.06M.
- Exome Asset Management's largest Q2 2026 buy was TG Therapeutics: 164,915 shares worth $9.06M.
- Exome Asset Management added most to Maze Therapeutics in Q2 2026, an estimated $686K increase.
- Exome Asset Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $5.78M.
- Exome Asset Management fully exited Elevance Health in Q2 2026, selling an estimated $4.3M.
- Exome Asset Management's ten largest holdings make up 45% of its $162M portfolio in Q2 2026.
- Exome Asset Management opened 15 new positions and closed 19 in Q2 2026.
- Exome Asset Management's portfolio value fell 16% quarter-over-quarter to $162M.
Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.